Working... Menu

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients (PD-SOAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01007630
Recruitment Status : Unknown
Verified November 2013 by Grace Liang, The Parkinson's Institute.
Recruitment status was:  Active, not recruiting
First Posted : November 4, 2009
Last Update Posted : December 2, 2013
Teva Neuroscience, Inc.
Information provided by (Responsible Party):
Grace Liang, The Parkinson's Institute

Brief Summary:

A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease.

Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: Rasagiline Drug: Placebo Phase 4

Detailed Description:

This study will last approximately 10 weeks.

  • 2 visits to The Parkinson's Institute in Sunnyvale, California
  • 1 phone call between visits

You will be asked to take either Rasagiline (Azilect) or placebo (an identical pill without active ingredients)

  • 5 in 6 chance of receiving Rasagiline (Azilect)
  • 1 in 6 chance of receiving placebo
  • Neither you nor the study team will know which you are assigned
  • This information will be available in case of emergency

To be eligible for this study, you must:

  • be 90 years old or younger
  • have a decreased loss of smell or complete loss of smell
  • have not taken Selegiline or Rasagiline within the past 12 months
  • have not smoked within the last year
  • be on a stable dose of Parkinson's medication (or not on any PD medicines)
  • have no history of head trauma, nasal surgery, nasal inflammation causing congestion or polyps, nasal/sinus infection, or prior Zicam use
  • have not used decongestants, antihistamine or inhaled steroids within 2 weeks of the study and be willing to avoid such treatments during the study

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease
Study Start Date : November 2009
Estimated Primary Completion Date : January 2014
Estimated Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Rasagiline
0.5mg of Rasagiline for 14 days, then switch to 1mg of Rasagiline for remainder of the study (approximately 10 weeks total).
Drug: Rasagiline
0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
Other Name: Brand Name: Azilect

Placebo Comparator: Placebo
0.5mg of placebo for 14 days, then switch to 1mg of placebo for remainder of the study (approximately 10 weeks total)
Drug: Placebo
0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)

Primary Outcome Measures :
  1. Change from baseline in UPSIT score at 10-week visit [ Time Frame: 10 weeks ]

Secondary Outcome Measures :
  1. Tolerability: Number of subjects (%) who discontinue the study due to AEs [ Time Frame: 10 weeks ]
  2. Safety: AE incidence [ Time Frame: 10 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 90 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women with Parkinson's Disease (PD), defined as the presence of at least two of the cardinal signs of PD (bradykinesia, resting tremor, rigidity) without other identifiable cause of parkinsonism or signs of atypical parkinsonism
  • Functional hyposmia or anosmia, as defined by UPSIT scores less than the 25th percentile for age- and gender-matched norms
  • Have been on stable dose of PD medications for at least 30 days
  • Age < or = 90 years
  • Willing and able to give informed consent
  • Women of child-bearing potential may participate provided they are willing to use adequate contraceptive methods during the duration of the study. Women of childbearing potential must have a negative pregnancy test at the screening visit and be non-lactating.

Exclusion Criteria:

  • Prior use of an MAO inhibitor, including selegiline or rasagiline within the last 12 months
  • Presence of other conditions that in the investigator's opinion may significantly cause olfactory impairment, including prior head trauma, nasal surgery, nasal inflammation causing concurrent congestion or polyps, nasal or sinus infection, prior intranasal zinc salt (Zicam) use, history of smoking within the past year
  • Presence of dementia or significant cognitive impairment with Mini-Mental State Examination (MMSE) < 24
  • Present of a medical or surgical condition which in the opinion of the investigator would preclude participation in and completion of study procedures
  • Use of any experimental medication within 60 days of baseline
  • Use of decongestants, antihistamines, inhaled steroids within 2 weeks of baseline
  • Use of any medication contraindicated with use of rasagiline (Investigator will take into consideration concomitant antidepressant use as per prescribing information guidelines for rasagiline)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01007630

Layout table for location information
United States, California
The Parkinson's Institute
Sunnyvale, California, United States, 94085
Sponsors and Collaborators
The Parkinson's Institute
Teva Neuroscience, Inc.
Layout table for investigator information
Principal Investigator: Grace S Liang, MD The Parkinson's Institute

Additional Information:
Layout table for additonal information
Responsible Party: Grace Liang, Principal Investigator, Director of Clinical Trials, The Parkinson's Institute Identifier: NCT01007630     History of Changes
Other Study ID Numbers: PD-SOAR
First Posted: November 4, 2009    Key Record Dates
Last Update Posted: December 2, 2013
Last Verified: November 2013

Keywords provided by Grace Liang, The Parkinson's Institute:
Parkinson's Disease
Sense of Smell

Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Monoamine Oxidase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs